What if we could tackle the
cause of Alzheimer’s and
Parkinson’s Disease?

Neurodegeneration
A hallmark of neurodegenerative diseases such as Alzheimer’s and Parkinson’s Disease, as well as rarer diseases such as Huntington’s Disease and Amyotrophic Lateral Sclerosis (ALS), is the appearance of cytotoxic, misfolded proteins. For example, it has long been known that the protein a-synuclein and the large aggregates of a-synuclein known as Lewy Bodies have been correlated with Parkinson’s Disease disease progression.
While functional a-synuclein is important for healthy brain function, excessive protein causes oligomers and aggregation, leading to neurotoxicity and the characteristic deadly symptoms of PD.
It’s likely that a-syn aggregation is caused by lysosomal misprocessing and that this dysfunction is in turn associated with dysfunctional autophagy
This hypothesis is underpinned by strong genetic evidence.
By restoring autophagy in such diseased cells we can remove the misfolded protein, such as a-synuclein, and restore lysosome function, something we have already shown in cells derived from early onset Alzheimer’s patients.



Accumulation of enlarged lysosomes in untreated neurons.
Significant reduction in lysosome area after 24h treatment with
SAM19272 (left) and SAM7559 (right).

Accumulation of enlarged lysosomes in untreated neurons.


Significant reduction in lysosome area after 24h treatment with SAM19272 and SAM7559.
Samsara compounds reverse the pathological accumulation of late endosomes and lysosomes in neurons derived from a patient with early onset Alzheimer’s Disease.
Samsara Therapeutics Establishes Scientific Advisory Board
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics
More additions to the Samsara Therapeutics team
We’re pleased to report that we’ve further strengthened our team in Oxford.
Neurodegeneration, lysosomal dysfunction and autophagy
There is a desperate need for novel therapies that can prevent the progressive neurodegeneration in debilitating diseases of ageing, such as Alzheimer’s, Parkinson’s and Huntington’s Disease.
New home and strengthening our scientific team
It’s a busy time for Samsara Therapeutics as we move into our new purpose-built labs and offices in the Wood Centre for Innovation in Oxford.
© 2021 Samsara Therapeutics | Legal Information | Privacy
© 2021 Samsara Therapeutics
Legal Information | Privacy